Status:
WITHDRAWN
Evaluation of a Novel Axillary Lymph Node Ink Localization Technique: A Feasibility Study
Lead Sponsor:
The Ottawa Hospital
Conditions:
Breast Cancer
Axillary Lymphadenitis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Patients with breast cancer and metastatic axillary lymphadenopathy routinely undergo neo-adjuvant chemotherapy. For these patients, biopsy clip markers are inserted into the biopsy proven metastatic ...
Eligibility Criteria
Inclusion
- English or French speaking female patients, with a personal history of current pathologically proven breast cancer, over the age of 18 years \[patients \<18 would be considered a rare occurrence\]
- Patients who will be undergoing neoadjuvant chemotherapy
- Patients who will be undergoing axillary lymph node radioactive seed localization
- Patients who will be undergoing axillary surgery
Exclusion
- Allergic reaction to Black Eye Ink or any of its components
- Pregnancy
- Confirmed metastatic disease
Key Trial Info
Start Date :
January 2 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 19 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04136496
Start Date
January 2 2020
End Date
June 19 2023
Last Update
April 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Ottawa Hospital
Ottawa, Ontario, Canada, K1Y1J7